Progress in Cardiovascular Diseases

Progress in Cardiovascular Diseases Journal

Publication venue for

Cardiovascular disease in space: A systematic review. 81:33-41. 2023
Introduction to assorted topics II 2023. 81:1-1. 2023
Multimodality imaging of hypertrophic cardiomyopathy. 80:14-24. 2023
Cardiovascular statistics 2023. 79:112-113. 2023
Introduction- Assorted topics 2023. 79:1-1. 2023
Lipoprotein(a) in clinical practice: A guide for the clinician. 79:28-36. 2023
PCSK9 inhibitor, ezetimibe, and bempedoic acid: Evidence-based therapies for statin-intolerant patients. 79:12-18. 2023
The common pathobiology between coronary artery disease and calcific aortic stenosis: Evidence and clinical implications. 79:89-99. 2023
Updates on obesity and the obesity paradox in cardiovascular diseases. 78:2-10. 2023
Leisure time versus occupational physical activity for cardiometabolic risk. 78:83-84. 2023
A decade as editor-in-chief of progress in cardiovascular diseases. 76:118-119. 2023
COVID-19, Unhealthy lifestyle behaviors and chronic disease in the United States: Mapping the social injustice overlay. 76:112-117. 2023
Impact of COVID-19 in patients hospitalized with stress cardiomyopathy: A nationwide analysis. 76:25-30. 2023
The response to the COVID-19 pandemic: With hindsight what lessons can we learn?. 76:76-83. 2023
Assessment of lifestyle-related risk factors enhances the effectiveness of cardiac stress. 77:95-106. 2023
Cardiology and lifestyle medicine. 77:4-13. 2023
Comparing eligibility for statin therapy for primary prevention under 2022 USPSTF recommendations and the 2018 AHA/ACC/ multi-society guideline recommendations: From National Health and Nutrition Examination Survey. 75:78-82. 2022
The associations between exercise and lipid biomarkers. 75:59-68. 2022
Debunking the vegan myth: The case for a plant-forward omnivorous whole-foods diet. 74:2-8. 2022
Introduction for assorted cardiovascular topics II. 74:1-1. 2022
Optimal periprocedural antithrombotic treatment in carotid interventions: An international, multispecialty, expert review and position statement. 74:28-37. 2022
Prosthesis-patient mismatch following aortic and mitral valves replacement - A comprehensive review. 72:84-92. 2022
A tale of two pandemics revisited: Physical inactivity, sedentary behavior and poor COVID-19 outcomes reside in the same Syndemic City. 71:69-71. 2022
Association of participation in Cardiac Rehabilitation with Social Vulnerability Index: The behavioral risk factor surveillance system. 71:86-91. 2022
Individual sentiments on telehealth in the COVID-19 era: Insights from Twitter. 71:100-102. 2022
Defining the importance of stress reduction in managing cardiovascular disease - the role of exercise. 70:84-93. 2021
Impact of cardiorespiratory fitness on outcomes in cardiac rehabilitation. 70:2-7. 2021
Impressive results with EPA, but EPA/DHA combinations also reduce cardiovascular outcomes. 69:110-112. 2021
From the editor's desk-overweight and obesity and obesity paradox in cardiovascular diseases. 68:106-107. 2021
Introduction to assorted topics II 2021. 68:1-1. 2021
Role of non-coding RNAs as biomarkers of deleterious cardiovascular effects in sepsis. 68:70-77. 2021
Beyond cardioversion, ablation and pharmacotherapies: Risk factors, lifestyle change and behavioral counseling strategies in the prevention and treatment of atrial fibrillation. 66:2-9. 2021
Emerging topics in electrophysiology. 66:1-1. 2021
Epidemiology, evaluation, and management of conduction disturbances after transcatheter aortic valve replacement. 66:37-45. 2021
Right ventricular lead location and outcomes among patients with cardiac resynchronization therapy: A meta-analysis. 66:53-60. 2021
The role of atrial fibrillation catheter ablation in patients with heart failure. 66:80-85. 2021
Cross-country skiing and running's association with cardiovascular events and all-cause mortality: A review of the evidence. 62:505-514. 2020
Physical activity without weight loss reduces the development of cardiovascular disease risk factors - a prospective cohort study of more than one hundred thousand adults. 62:522-530. 2020
Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): Evidence from a meta-analysis. 63:390-391. 2020
Cross-country skiing and running's association with cardiovascular events and all-cause mortality: A review of the evidence. 62:505-514. 2020
Hypertension 2020 update: A view from the Crescent City and beyond. 63:1-1. 2020
Impact of therapeutic lifestyle changes in resistant hypertension. 63:4-9. 2020
Left ventricular hypertrophy and hypertension. 63:10-21. 2020
Non-statin interventions in the prevention of cardiovascular events: Sex-based meta-analysis. 63:228-232. 2020
PCVD 2020. 63:74-75. 2020
Physical activity without weight loss reduces the development of cardiovascular disease risk factors - a prospective cohort study of more than one hundred thousand adults. 62:522-530. 2020
Physical exercise as therapy to fight against the mental and physical consequences of COVID-19 quarantine: Special focus in older people. 63:386-388. 2020
Renal denervation: Alternative treatment options for hypertension?. 63:51-57. 2020
Renal revascularization in resistant hypertension. 63:58-63. 2020
Special Article - Lipoprotein(a) and calcific aortic valve stenosis: A systematic review. 63:496-502. 2020
Special assorted cardiovascular topics. 63:193-193. 2020
Statistics 2020 at Progress in Cardiovascular Diseases. 63:534-535. 2020
We all need a yellow submarine!. 63:389-389. 2020
Advances in the Risk Stratification, Prevention, and Treatment of Sudden Check for updates Cardiac Death. 62:203-204. 2019
An update on pharmacotherapies in diabetic dyslipidemia. 62:334-341. 2019
Cardiorespiratory Fitness and Physical Activity: Two Important but Distinct Clinical Measures with Different Degrees of Precision - A Commentary. 62:74-75. 2019
Continuing with Good Statistics at Progress in Cardiovascular Diseases. 62:370-372. 2019
Diabetic cardiomyopathy - A comprehensive updated review. 62:315-326. 2019
Five Years as Editor-in-Chief. 62:83-84. 2019
Non-arrhythmic causes of sudden death: A comprehensive review. 62:265-271. 2019
Obesity, risk of diabetes and role of physical activity, exercise training and cardiorespiratory fitness. 62:327-333. 2019
Sudden cardiac death in Long QT syndrome (LQTS), Brugada syndrome, and catecholaminergic polymorphic ventricular tachycardia (CPVT). 62:227-234. 2019
Sudden cardiac death in nonischemic cardiomyopathy. 62:235-241. 2019
The elephant in the room: Why cardiologists should stop ignoring type 2 diabetes. 62:364-369. 2019
The role of cardiorespiratory fitness on the risk of sudden cardiac death at the population level: A systematic review and meta-analysis of the available evidence. 62:279-287. 2019
The wearable cardioverter-defibrillator vest: Indications and ongoing questions. 62:256-264. 2019
Advances in Echocardiography. 61:389-389. 2018
Alcohol and CV Health: Jekyll and Hyde J-Curves. 61:68-75. 2018
An Overview and Update on Obesity and the Obesity Paradox in Cardiovascular Diseases. 61:142-150. 2018
Coffee for Cardioprotection and Longevity. 61:38-42. 2018
Dual (Anticoagulant Plus Single Antiplatelet) vs Triple (Anticoagulant Plus Dual Antiplatelet) Antithrombotic Therapy - "Real World" Experience. 60:531-536. 2018
Duration of Dual Antiplatelet Therapy Following Drug-Eluting Stent Implantation in Diabetic and Non-Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. 60:500-507. 2018
Echocardiography in Congenital Heart Disease. 61:468-475. 2018
Four Years as Editor-in-Chief. 60:560-561. 2018
Introduction and Update on Obesity and Cardiovascular Diseases 2018. 61:87-88. 2018
Omega-3 Polyunsaturated Fatty Acids and Cardiovascular Health: A Comprehensive Review. 61:76-85. 2018
Prognostic Implications of Left Ventricular Hypertrophy. 61:446-455. 2018
Role of Transesophageal Echocardiography in Patients with Ischemic Stroke. 61:456-467. 2018
The Contributions of 'Diet', 'Genes', and Physical Activity to the Etiology of Obesity: Contrary Evidence and Consilience. 61:89-102. 2018
The Fluctuating Journal Statistics. 61:270-271. 2018
The Waxing and Waning of Antithrombotic Therapy in Cardiovascular Disease - Where Is the Moon Now?. 60:457-459. 2018
Changing our Approach to Stage D Heart Failure. 60:205-214. 2017
Endovascular Treatment of Vertebral Artery Stenosis. 59:619-625. 2017
From Heart Failure to Journal Metrics-Making Progress in Cardiovascular Diseases. 60:281-283. 2017
Healthy Living: The Universal and Timeless Medicine for Healthspan. 59:419-421. 2017
Impact of cardiac rehabilitation and exercise training programs in coronary heart disease. 60:103-114. 2017
Initial Assessment and Triage of the Stroke Patient. 59:527-533. 2017
Neuroprotection in the Treatment of Acute Ischemic Stroke. 59:542-548. 2017
Overcoming Potential Threats to Scientific Advancements: Conflict of Interest, Ulterior Motives, False Innuendos and Harassment. 59:522-524. 2017
Pharmacologic Therapy for Heart Failure With Reduced Ejection Fraction: Closing the Gap Between Clinical Guidelines and Practice. 60:187-197. 2017
Public Park Spaces as a Platform to Promote Healthy Living: Introducing a HealthPark Concept. 60:152-158. 2017
Stroke Treatment and Prevention. 59:525-526. 2017
Taking Physical Activity, Exercise, and Fitness to a Higher Level. 60:1-2. 2017
The Interaction of Cardiorespiratory Fitness With Obesity and the Obesity Paradox in Cardiovascular Disease. 60:30-44. 2017
The P4 Health Spectrum - A Predictive, Preventive, Personalized and Participatory Continuum for Promoting Healthspan. 59:506-521. 2017
The Role of Technology in Healthy Living Medicine. 59:487-491. 2017
Three Years as Editor-in-Chief. 59:417-418. 2017
Training Health Professionals to Deliver Healthy Living Medicine. 59:471-478. 2017
Analyzing 2015 Impact Factors - Special Editor's Commentary. 59:323-324. 2016
Current Perspectives on Left Ventricular Geometry in Systemic Hypertension. 59:235-246. 2016
Emerging Trends and Current Controversies in Heart Failure. 58:461-462. 2016
Exercise Training in Group 2 Pulmonary Hypertension: Which Intensity and What Modality. 59:87-94. 2016
Lifestyle Choices Fuel Epidemics of Diabetes and Cardiovascular Disease Among Asian Indians. 58:505-513. 2016
New Concepts in Hypertension Management: A Population-Based Perspective. 59:289-294. 2016
Obesity and Prevalence of Cardiovascular Diseases and Prognosis-The Obesity Paradox Updated. 58:537-547. 2016
Renal Denervation for Resistant Hypertension. 59:295-302. 2016
The Role of Technology in Chronic Disease Care. 58:579-583. 2016
Update on Obesity and Obesity Paradox in Heart Failure. 58:393-400. 2016
Advances in the Prevention and Treatment of Atrial Fibrillation. 58:103-104. 2015
Atrial Fibrillation and Heart Failure: Update 2015. 58:126-135. 2015
Changing the Endpoints for Determining Effective Obesity Management. 57:330-336. 2015
Development and Implementation of Worksite Health and Wellness Programs: A Focus on Non-Communicable Disease. 58:94-101. 2015
Endothelial Dysfunction and Lung Capillary Injury in Cardiovascular Diseases. 57:454-462. 2015
Lifestyle Modification in the Prevention and Treatment of Atrial Fibrillation. 58:117-125. 2015
Part 1: Potential Dangers of Extreme Endurance Exercise: How Much Is Too Much? Part 2: Screening of School-Age Athletes. 57:396-405. 2015
Physical Activity and Cardiorespiratory Fitness as Major Markers of Cardiovascular Risk: Their Independent and Interwoven Importance to Health Status. 57:306-314. 2015
Role of Fitness in the Metabolically Healthy but Obese Phenotype: A Review and Update. 58:76-86. 2015
What Is Ischemia and How Should This Be Defined Based on Modern Imaging?. 57:537-554. 2015
Cardiac Rehabilitation in the Elderly. 57:152-159. 2014
Clinical Characteristics, Treatment Patterns and Outcomes of Hispanic Hypertensive Patients. 57:244-252. 2014
Hispanics and Cardiovascular Health and the "Hispanic Paradox": What is Known and What Needs to be Discovered?. 57:227-229. 2014
Impact of Echocardiographic Left Ventricular Geometry on Clinical Prognosis. 57:3-9. 2014
Low Weight and Overweightness in Older Adults: Risk and Clinical Management. 57:127-133. 2014
Obesity and Prognosis-Just One of Many Cardiovascular Paradoxes?. 56:367-368. 2014
The Impact of Obesity on Risk Factors and Prevalence and Prognosis of Coronary Heart Disease-The Obesity Paradox. 56:401-408. 2014
The Role of Exercise and Physical Activity in Weight Loss and Maintenance. 56:441-447. 2014
Coronary Angiography Is the Gold Standard for Patients with Significant Left Ventricular Dysfunction. 55:504-508. 2013
Benefits of Exercise Therapy in Peripheral Arterial Disease. 53:447-453. 2011
Cardiac Rehabilitation and Exercise Training in Secondary Coronary Heart Disease Prevention. 53:397-403. 2011
Chronic Mesenteric Ischemia: Diagnosis and Management. 54:36-40. 2011
Endovascular Therapies to Treat Iliofemoral Deep Venous Thrombosis. 54:70-76. 2011
Exercise and Cardiovascular Diseases-a Matter of Life or Death Introduction. 53:385-386. 2011
Impact of Exercise Training on Psychological Risk Factors. 53:464-470. 2011
UPDATES IN VASCULAR MEDICINE AND ENDOVASCULAR INTERVENTION Introduction. 54:1-1. 2011
Clinical Impact of Left Ventricular Hypertrophy and Implications for Regression. 52:153-167. 2009
Management of Renal Artery Stenosis: The Case for Intervention, Defending Current Guidelines, and Screening (Drive-By) Renal Angiography at the Time of Catheterization. 52:229-237. 2009

International Standard Serial Number (ISSN)

0033-0620